Assistant Clinical Professor of Medicine, University Mich Medical School
Oncology
Dr. Francis P. Worden, MD
|
|
Give Review
Francis Worden works in the field of Oncology. He attended Indiana University School of Medicine. Indiana University School of Medicine has a rank of 45 in research and a 47 in primary care He over the years received 3 awards: "America's Top Doctors for Cancer", "America's Top Doctors" and "CMS Meaningful Use Stage 1 Certification". Francis Worden is a published MD as well. He has 69 publications published. The latest was: Exploration for an Algorithm for Deintensification to Exclude the Retropharyngeal Site From Advanced Oropharyngeal Squamous Cell Carcinoma Treatment. Doctor Francis P. Worden, MD accepts Medicare payments and is registered with Medicare.gov.
Publications
- Comparisons of dysphagia and quality of life (QOL) in comparable patients with HPV-positive oropharyngeal Cancer receiving chemo-irradiation or cetuximab-irradiation.
- Exploration for an Algorithm for Deintensification to Exclude the Retropharyngeal Site From Advanced Oropharyngeal Squamous Cell Carcinoma Treatment.
- Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic Carcinoma and for nonadenoid cystic malignant salivary tumors.
- Advanced oropharyngeal squamous Cell carcinoma: Pathogenesis, treatment, and novel therapeutic approaches.
- Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical Carcinoma: a double-blind, randomised, phase 3 study.
- Adjuvant Radiation Therapy Improves Local Control After Surgical Resection in Patients With Localized Adrenocortical Carcinoma.
- Efficacy of Vismodegib (Erivedge) for Basal Cell Carcinoma Involving the Orbit and Periocular Area.
- Trends in imaging after diagnosis of thyroid Cancer.
- Treatment strategies for radioactive iodine-refractory differentiated thyroid Cancer.
- Conditional Survival in Thyroid Cancer Patients.
- Erratum to: The Combination of Insulin-Like Growth Factor Receptor 1 (IGF1R) Antibody Cixutumumab and Mitotane as a First-Line Therapy for Patients with Recurrent/Meta...
- Matted Nodes Predict Distant Metastasis in Advanced Stage III/IV Oropharyngeal Squamous Cell Carcinoma.
- Phase I trial of radiotherapy concurrent with twice-weekly gemcitabine for head and neck Cancer: translation from preclinical investigations aiming to improve the ther...
- The Combination of Insulin-Like Growth Factor Receptor 1 (IGF1R) Antibody Cixutumumab and Mitotane as a First-Line Therapy for Patients with Recurrent/Metastatic Adren...
- Nonendemic HPV-Positive Nasopharyngeal Carcinoma: Association With Poor Prognosis.
- Refining risk stratification for locoregional failure after chemoradiotherapy in human papillomavirus-associated oropharyngeal Cancer.
- Efficacy of induction selection chemotherapy vs primary surgery for patients with advanced oral cavity Carcinoma.
- Reliability of post-chemoradiotherapy F-18-FDG PET/CT for prediction of locoregional failure in human papillomavirus-associated oropharyngeal Cancer.
- Human papillomavirus-related oropharyngeal Cancer: HPV and p16 status in the recurrent versus parent tumor.
- A phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous Cell carcinoma of the head and neck (SCCHN): SWOG study S0329.
- High-Risk Human Papillomavirus Detection in Oropharyngeal, Nasopharyngeal, and Oral Cavity Cancers: Comparison of Multiple Methods.
- Outcomes Evaluation of a Weekly Nurse Practitioner-Managed Symptom Management Clinic for Patients With Head and Neck Cancer Treated With Chemoradiotherapy.
- Chemoselection: a paradigm for optimization of organ preservation in locally advanced larynx Cancer.
- Vismodegib as Eye-Sparing Adjuvant Treatment for Orbital Basal Cell Carcinoma.
- Patterns of nodal metastasis and prognosis in human papillomavirus positive oropharyngeal squamous Cell carcinoma.
- Head & neck squamous Cell carcinoma of unknown primary: Neck dissection and radiotherapy or definitive radiotherapy.
- Marginal treatment benefit in anaplastic thyroid Cancer.
- CT Perfusion Can Predict Overexpression of CXCL8 (Interleukin-8) in Head and Neck Squamous Cell Carcinoma.
- Circulating CD4-positive lymphocyte levels as predictor of response to induction chemotherapy in patients with advanced laryngeal Cancer.
- Aspiration pneumonia after chemo-intensity-modulated radiation therapy of oropharyngeal Carcinoma and its clinical and dysphagia-related predictors.
- Biomarkers in advanced larynx Cancer: Triological society thesis.
- Neck spasm after chemoradiotherapy for head and neck Cancer: Natural history and dosimetric correlates.
- Weekly chemotherapy with radiation versus high-dose cisplatin with radiation as organ preservation for patients with HPV positive and HPV negative locally advanced squ...
- Head and neck squamous Cell carcinoma in pregnant women.
- Inactivation or Loss of TTP Promotes Invasion in Head and Neck Cancer via Transcript Stabilization and Secretion of MMP9, MMP2, and IL-6.
- Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous Cell carcinoma of the head and neck.
- Matted nodes: Poor prognostic marker in oropharyngeal squamous Cell carcinoma independent of HPV and EGFR status.
- Osteocutaneous Free Tissue Transplantation for Mandibular Osteoradionecrosis.
- Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous Cell carcinoma.
- Diagnostic modalities for distant metastasis in head and neck squamous Cell carcinoma: are we changing life expectancy?
- Metronomic dosing of BH3 mimetic small molecules yields robust anti-angiogenic and anti-tumor effects.
- Mebendazole Monotherapy Provides Long-Term Disease Control in Metastatic Adrenocortical Carcinoma.
- A phase II study of imatinib in patients with advanced anaplastic thyroid Cancer.
- Chemotherapy alone for organ preservation in advanced laryngeal Cancer.
- Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung Cancer.
- Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal Cancer: clinical and functional results.
- HPV-positive/p16-positive/EBV-negative nasopharyngeal Carcinoma in white North Americans.
- Sinonasal undifferentiated Carcinoma: a 13-year experience at a single institution.
- Tobacco use in human papillomavirus-positive advanced oropharynx Cancer patients related to increased risk of distant metastases and tumor recurrence.
- High SEPT9_v1 Expression Is Associated with Poor Clinical Outcomes in Head and Neck Squamous Cell Carcinoma.
- Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous Cell carcinoma with cartilage invasion.
- Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung Cancer.
- Early prediction of outcome in advanced head-and-neck Cancer based on tumor blood volume alterations during therapy: a prospective study.
- Phase II study of celecoxib and docetaxel in non-small cell lung Cancer (NSCLC) patients with progression after platinum-based therapy.
- Axitinib is an active treatment for all histologic subtypes of advanced thyroid Cancer: results from a phase II study.
- Controversies in the management of oropharynx Cancer.
- Chemoselection as a strategy for organ preservation in advanced oropharynx Cancer: response and survival positively associated with HPV16 copy number.
- EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal Cancer.
- Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma.
- Use of warfarin in the patient with Cancer.
- Acceleration of hyperfractionated chemoradiation regimen for advanced head and neck Cancer.
- Response to therapy and outcomes in oropharyngeal Cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and s...
- Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck Cancer.
- Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical Carcinoma.
- Metabolic abnormalities associated with weight loss during chemoirradiation of head-and-neck Cancer.
- Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxo...
- Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid Gland sparing.
- Carboplatin-pemetrexed in treatment of patients with recurrent/metastatic Cancers of the head and neck; superior outcomes in oropharyngeal primaries.
Schools
Indiana University School of Medicine
Wayne State University
Wayne State University Detroit Med Center
University MichU Mich Hospital
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors for Cancer
- America's Top Doctors
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Michigan Hospitals and Health Centers -
Indiana University School of Medicine
Hospital
-
University of Michigan Hospitals and Health Centers
Drug Facts
| NPI NUMBER | 1700962677 | |
| NPPES Provider LastName | WORDEN | |
| NPPES Provider FirstName | FRANCIS | |
| NPPES Provider ZIPCode | 481095912 | |
| NPPES Provider State | MI | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 1176.0 | |
| Distinct Opioid Count | 6.0 | |
| Opioid Claim Count | 203.0 | |
| Percent Opioid Claims | 17.26 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1700962677 |
| Last Name Of The Provider | WORDEN |
| First Name Of The Provider | FRANCIS |
| View All |
Similar Doctors
|
|
Dr. Max S. Wicha, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Susan G. Urba, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kathleen A. Cooney, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Douglas W. Blayney, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dean E. Brenner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kunal C. Kadakia, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Theodora S. Ross, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Assuntina G. Sacco, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scott M. Schuetze, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer J. Griggs, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Sofia D. Merajver, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Muneesh Tewari, MD
This Doctor is OpenDoctor Recommended.
|